Duaklir Pressair (Formoterol)

Generic Name

Formoterol

Brand Names

Duaklir Pressair, Perforomist

FDA approval date: October 01, 2007

Classification: beta2-Adrenergic Agonist

Form: Powder, Solution

What is Duaklir Pressair (Formoterol)?

DUAKLIR PRESSAIR is a combination of aclidinium bromide and formoterol fumarate indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease . Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

Enrollment Status: Recruiting

Publish Date: June 15, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic trea...

A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

Enrollment Status: Recruiting

Publish Date: May 13, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) Versus Placebo in Participants of 4 to Less Than 12 Years of Age With Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF)

Enrollment Status: Recruiting

Publish Date: April 22, 2026

Intervention Type: Combination product

Study Phase: Phase 2

Summary: The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.

View All Clinical Trials